$1.13 +0.08 (%) Amarin Corp Shs Sponsored American Deposit Receipt Repr 1 Sh - NASDAQ

Dec. 19, 2014 | 04:00 PM

Partner Headlines

  1. Week Concludes With S&P 500 Below 2,000; Dow Below 17,000

    Benzinga | Sep. 12, 2014 | 16:51PM EST
  2. Dow Falls Over 100 Points; Ulta Salon Shares Jump After Earnings Report

    Benzinga | Sep. 12, 2014 | 15:59PM EST
  3. Conversant Shares Rise On Acquisition News; Health Care REIT Drops

    Benzinga | Sep. 12, 2014 | 14:02PM EST
  4. Markets Drop; Darden Adjusted Profit Beats Street View

    Benzinga | Sep. 12, 2014 | 11:26AM EST
  5. Morning Market Losers

    Benzinga | Sep. 12, 2014 | 09:45AM EST
  6. Amarin Moves Higher On Speculation Of Special Protocol Assessment

    Benzinga | Jul. 31, 2014 | 12:01PM EST
  7. Top Performing Industries For June 12, 2014

    Benzinga | Jun. 12, 2014 | 10:28AM EST
  8. FDA Approvals And Changes For The Week Ending February 14, 2014

    Benzinga | Feb. 18, 2014 | 16:17PM EST
  9. Amarin Announces FDA DMEP Does Not Plan to Re-instate ANCHOR SPA Agreement

    Benzinga | Jan. 21, 2014 | 05:46AM EST
  10. Benzinga's Top #PreMarket Losers

    Benzinga | Jan. 16, 2014 | 08:22AM EST
  11. Amarin Announces FDA Review Division Response on ANCHOR SPA Agreement Reinstatement Request Will Be Delayed

    Benzinga | Jan. 15, 2014 | 16:05PM EST
  12. FDA Delays Decision on Amarin's Vascepa Drug

    Benzinga | Dec. 20, 2013 | 12:46PM EST
  13. Amarin Receives FDA Notification That Action on ANCHOR sNDA Review Will be Delayed

    Benzinga | Dec. 20, 2013 | 06:03AM EST
  14. Amarin's Vascepa: Too Limited A Market Or FDA Blunder?

    Benzinga | Dec. 18, 2013 | 14:11PM EST
  15. Amarin Announces Notification of Patent Allowances Related to Triglyceride Lowering With a Mixture of Omega-3 Free Fatty Acid (Including EPA and/or DHA) in Both the MARINE and ANCHOR Patient Populations

    Benzinga | Dec. 2, 2013 | 06:05AM EST
  16. New Statin Rules: Which Drugmakers Had Ties?

    YCharts | Nov. 14, 2013 | 19:39PM EST
  17. Is Amarin’s Fish Oil Blockbuster Dream Kaput?

    YCharts | Nov. 9, 2013 | 03:03AM EST
  18. UPDATE: Citigroup Upgrades Amarin on Valuation

    Benzinga | Nov. 8, 2013 | 09:31AM EST
  19. Benzinga's Top Upgrades

    Benzinga | Nov. 8, 2013 | 07:29AM EST
  20. Aegis Capital Corp. Reiterates on Amarin Corporation plc After FDA Formally Rescinds Special Protocol Assessment

    Benzinga | Oct. 30, 2013 | 11:00AM EST
  21. Market Wrap For Thursday, October 17: S&P Record High On Debt Deal

    Benzinga | Oct. 17, 2013 | 16:41PM EST
  22. Mid-Day Market Update: SanDisk Surges On Upbeat Results; IBM Shares Tumble

    Benzinga | Oct. 17, 2013 | 12:59PM EST
  23. Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Revenue Drops 20%

    Benzinga | Oct. 17, 2013 | 11:10AM EST
  24. Stocks Hitting 52-Week Lows

    Benzinga | Oct. 17, 2013 | 10:10AM EST
  25. UPDATE: Aegis Capital Downgrades Amarin Following Negative Panel Vote on Vascepa

    Benzinga | Oct. 17, 2013 | 09:14AM EST
  26. Benzinga's Top Pre-Market Losers

    Benzinga | Oct. 17, 2013 | 08:16AM EST
  27. Amarin Announces Negative FDA Advisory Committee Outcome for the Use of Vascepa in the Treatment of High Triglycerides With Mixed Dyslipidemia

    Benzinga | Oct. 16, 2013 | 16:20PM EST
  28. Amarin Halted Ahead of FDA Advisory Committee to Review sNDA for Vascepa( ANCHOR Indication

    Benzinga | Oct. 16, 2013 | 05:56AM EST
  29. Aegis Says FDA's Outlook 'Not As Negative As People Think' on Amarin

    Benzinga | Oct. 14, 2013 | 13:30PM EST
  30. Aegis Capital Reiterates Buy on Amarin Corporation Following Release of Vascepa Briefing Documents

    Benzinga | Oct. 14, 2013 | 10:47AM EST
  31. Jefferies Reiterates Buy on Amarin Corporation on Continued Positive Outlook

    Benzinga | Oct. 10, 2013 | 12:20PM EST
  32. Goldman Sachs Reiterates Neutral on Amarin Ahead of Advisory Panel

    Benzinga | Oct. 9, 2013 | 11:26AM EST
  33. Amarin Shares Up 5% as FDA Says October 16th Advisory Committee Meeting Will Take Place as Scheduled

    Benzinga | Oct. 3, 2013 | 08:56AM EST
  34. Enrollment in Amarin REDUCE-IT Cardiovascular Outcomes Study Surpasses 6,000 Patients

    Benzinga | Sep. 25, 2013 | 06:33AM EST
  35. Amarin Reports 30th Patent for Vascepa

    Benzinga | Sep. 9, 2013 | 07:20AM EST
  36. Amarin Submits Supplemental NDA for Novasep as Fourth Vascepa Active Pharmaceutical Ingredient Supplier

    Benzinga | Aug. 26, 2013 | 06:02AM EST
  37. UPDATE: Citigroup Raises PT on Amarin Following Lighter 2Q13 Sales

    Benzinga | Aug. 12, 2013 | 08:36AM EST
  38. UPDATE: Jefferies Lowers PT on Amarin on Continued ANCHOR Partnership Discussion

    Benzinga | Aug. 9, 2013 | 12:33PM EST
  39. Amarin Announces USPTO Allowance for Application 13/614,129 Related to Vascepa and FDA Approved MARINE Indication

    Benzinga | Feb. 11, 2013 | 23:02PM EST
  40. Amarin Announces Patent Allowance Related to Vascepa and FDA Approved MARINE Indication

    Benzinga | Jan. 11, 2013 | 00:33AM EST
  41. Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN

    GuruFocus | Jan. 7, 2013 | 04:34AM EST
  42. Benzinga's Top Pre-Market Gainers

    Benzinga | Jan. 7, 2013 | 01:12AM EST
  43. Amarin Completes Dosing in a Fixed-Dose Combination Study With Vascepa and a Leading Statin

    Benzinga | Dec. 17, 2012 | 00:36AM EST
  44. Amarin Closes Dosing in Fixed-Dose Combination Study with Vascepa

    Benzinga | Dec. 17, 2012 | 00:33AM EST
  45. FDA's Orange Book Doesn't Include Amarin's Vascepa NCE Status in November Report - Bloomberg

    Benzinga | Dec. 14, 2012 | 07:40AM EST
  46. Benzinga's Top Pre-Market Gainers

    Benzinga | Dec. 13, 2012 | 01:10AM EST
  47. Amarin Receives Patent Allowance for Application 13/623,450 Related to Vascepa(R)

    Benzinga | Dec. 13, 2012 | 00:33AM EST
  48. Amarin Announces David Stack Appointed to Board of Directors

    Benzinga | Dec. 12, 2012 | 00:54AM EST
  49. Amarin Spikes Lower

    Benzinga | Dec. 11, 2012 | 03:11AM EST
  50. UDPATE: Aegis Capital Raises PT on Amarin to $35

    Benzinga | Dec. 7, 2012 | 08:48AM EST
Trading Center